Viewing Study NCT05738434


Ignite Creation Date: 2025-12-25 @ 2:24 AM
Ignite Modification Date: 2026-01-07 @ 12:10 PM
Study NCT ID: NCT05738434
Status: RECRUITING
Last Update Posted: 2024-11-21
First Post: 2023-02-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
Sponsor: The First Affiliated Hospital of Zhengzhou University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module